INZY vs IDE Comparison

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.